Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

Brief Summary

Official Title: “Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons”

The primary purpose of this study is to evaluate the association between nonalcoholic fatty liver disease (NAFLD) by computed tomography (CT) scan and coronary artery disease (CAD) measured by the calcium (CAC) score among HIV-infected persons.

  • Study Type: Observational
  • Study Design: Observational Model: Cohort, Time Perspective: Cross-Sectional
  • Study Primary Completion Date: March 2010

Outcome Measures for this Clinical Trial

Primary Measures

  • Coronary artery disease (CAD) measured by the CAC score
    • Time Frame: 1 year
      Safety Issue?: No

Secondary Measures

  • To determine the prevalence of coronary artery disease as determined by computed tomography (CT) of the coronary arteries among HIV patients, and to compare it to data from the general population using normative data from recent publications
    • Time Frame: 1 year
      Safety Issue?: No
  • To evaluate predictors for coronary artery disease including demographics, concurrent conditions (e.g., diabetes, hyperlipidemia, tobacco use), and HIV factors such as ARV duration, HIV duration, and lipodystrophy
    • Time Frame: 1 year
      Safety Issue?: No
  • To investigate the relationship between inflammatory markers (CRP, ESR), d-dimer, adiponectin levels, future inflammatory markers, and genetic polymorphisms with the presence of coronary disease and NAFLD
    • Time Frame: 1 year
      Safety Issue?: No
  • To assess the relationship between increased pericardial fat on CT scan with visceral fat and cardiovascular disease
    • Time Frame: 1 year
      Safety Issue?: No
  • To determine if Hounsfield units taken in the heart and aorta estimates hemoglobin levels
    • Time Frame: 1 year
      Safety Issue?: No
  • To measure the pulmonary artery size to evaluate for prevalence of asymptomatic pulmonary hypertension among HIV-infected persons
    • Time Frame: 1 year
      Safety Issue?: No
  • To describe the outcome of a positive CAC score in terms of follow-up test/procedure results to help describe the clinical significance of elevated scores.
    • Time Frame: 1 year
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • HIV patients who participated in our previous Liver Study, conducted at NMCSD, and HIV patients who did not participate in the Liver Study.

Exclusion Criteria

  • Women who are pregnant or breastfeeding will be excluded.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • Uniformed Services University of the Health Sciences
  • Collaborator
    • Infectious Diseases Clinical Research Program
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Nancy Crum-Cianflone, Department Head, US Department of Defense Center for Deployment Health Research – Naval Health Research Center

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00889577